cmv
caus
symptom
almost
organ
well
unspecif
symptom
fever
malais
bone
marrow
suppress
stem
cell
transplant
patient
howev
import
clinic
entiti
allohsct
patient
pneumonia
gastroenter
retin
likelihood
symptomat
infect
much
higher
allohsct
compar
autohsct
cmv
seroposit
cmv
also
associ
decreas
os
allohsct
use
cmv
donor
cmvseroneg
cmv
patient
patient
undergo
mac
allohsct
use
cmv
donor
cmv
patient
associ
increas
risk
nrm
decreas
os
addit
proof
cmv
replic
associ
increas
nrm
effect
risk
leukemia
relaps
controversi
cmv
antibodi
statu
determin
pretranspl
patient
undergo
hsct
allogen
stem
cell
donor
allohsct
patient
monitor
weekli
cmv
replic
sensit
diagnost
techniqu
least
first
month
hsct
patient
gvhd
document
cmv
replic
monitor
longer
need
routin
monitor
patient
autolog
hsct
commonli
use
techniqu
qpcr
also
socal
antigenemia
assay
test
detect
cmv
nucleic
acid
use
recent
test
detect
cmvspecif
tcell
becom
avail
evalu
test
use
routin
care
necessari
diagnos
cmv
diseas
import
combin
symptom
sign
document
presenc
cmv
affect
tissu
except
cmv
retin
ophthalmolog
find
characterist
although
detect
cmv
vitreou
fluid
help
establish
techniqu
detect
cmv
tissu
histopatholog
immunohistochemistri
dna
hybrid
high
level
cmv
dna
bal
associ
cmv
pneumonia
absenc
almost
exclud
cmv
pneumonia
pcr
csf
support
diagnosi
cmv
enceph
endorgan
diseas
qpcr
need
addit
studi
letermovir
shown
placebocontrol
random
trial
decreas
risk
clinic
signific
cmv
infect
need
preemptiv
antivir
therapi
andor
cmv
diseas
also
decreas
allcaus
mortal
cmv
patient
ganciclovir
reduc
risk
cmv
diseas
associ
signific
toxic
highdos
acyclovirvalaciclovir
reduc
risk
cmv
replic
data
regard
prophylact
ig
conflict
use
current
recommend
ganciclovir
valganciclovir
foscarnet
shown
effect
prevent
develop
cmv
diseas
allohsct
recipi
use
socal
preemptiv
therapi
base
detect
cmv
blood
efficaci
similar
choic
base
risk
side
effect
practic
aspect
possibl
give
recommend
cmv
dna
level
preemptiv
therapi
initi
sinc
depend
patient
factor
materi
use
monitor
plasmawhol
blood
perform
assay
use
therapi
usual
given
least
week
longer
therapi
cours
might
need
second
episod
cmv
replic
common
secondlin
therapi
given
either
antivir
drug
mention
ganciclovir
valganciclovir
foscarnet
use
drug
cmv
diseas
addit
highdos
ig
treatment
cmv
pneumonia
commonli
use
data
support
combin
limit
data
support
addit
ig
antivir
treatment
type
cmv
diseas
cidofovir
consid
failur
therapi
durat
therapi
decid
casebycas
basi
normal
longer
therapi
need
compar
preemptiv
therapi
week
cidofovir
also
possibl
secondor
thirdlin
antivir
therapi
new
antivir
drug
develop
proven
efficaci
indic
leflunomid
artesun
test
data
support
use
limit
sever
group
tri
prevent
treat
cmv
infect
diseas
follow
allohsct
transfer
cmvspecif
tcell
tcell
line
clone
specif
cmv
mostli
deriv
hsc
donor
studi
also
thirdparti
donor
even
patientderiv
cmvspecif
tcell
obtain
patient
prior
condit
therapi
new
strategi
appli
select
cmvspecif
tcell
without
longterm
vitro
cultur
thu
techniqu
like
cytokin
captur
assay
combin
miltenyi
clinimac
system
tetram
pentam
streptam
appli
gener
cmvspecif
tcell
prophylact
therapeut
transfer
transfer
cell
shown
reconstitut
virusspecif
tcell
immun
given
therapeut
patient
chemotherapyrefractori
cmv
infect
drop
viral
load
increas
number
cmvspecif
tcell
could
document
patient
chemotherapyrefractori
cmv
infect
posthsct
adopt
tcell
therapi
valid
therapeut
option
efficaci
patient
receiv
highdos
mgkg
corticosteroid
like
low
primari
infect
far
associ
specif
symptom
primari
infect
main
caus
exanthema
subitum
young
children
also
associ
febril
seizur
almost
children
infect
age
year
main
caus
viral
enceph
allohsct
also
document
patient
undergo
cbt
increas
risk
symptom
suggest
associ
bone
marrow
suppress
pneumonia
acut
gvhd
serolog
help
dna
analyz
blood
qpcr
use
monitor
establish
integr
germlin
individu
strongli
posit
qpcr
proof
viral
replic
mri
recommend
diagnosi
enceph
typic
find
limbic
enceph
pattern
also
seen
dna
usual
posit
csf
patient
enceph
foscarnet
use
use
establish
either
ganciclovir
foscarnet
use
treatment
enceph
establish
treatment
infect
patient
suspect
complic
cellular
immunotherapi
perform
patient
primari
infect
young
children
occasion
caus
exanthema
subitum
roseola
rare
statu
epilepticu
fever
nearli
children
infect
age
year
detect
hsct
rel
infrequ
rare
case
associ
cn
diseas
enceph
myeliti
risk
infect
hsct
patient
allo
auto
tbibas
chemobas
children
adult
reactiv
occur
patient
allohsct
dna
qpcr
might
cofactor
cmv
reactiv
use
infect
requir
specif
treatment
kshv
kaposi
sarcomaassoci
herpesviru
caus
kaposi
sarcoma
ks
primari
effus
lymphoma
multicentr
castleman
diseas
preval
kshv
infect
high
africa
part
amazon
basin
ks
rare
hsct
case
describ
fever
marrow
aplasia
plasmacytosi
hsct
occur
skin
involv
domin
clinic
present
adult
pediatr
case
viscer
involv
detect
dna
qpcr
ks
clinic
defin
basi
characterist
skin
lesion
histopatholog
defin
malign
tumor
recommend
diseas
limit
skin
surgic
excis
electrochemotherapi
prefer
approach
viscer
dissemin
diseas
possibl
option
includ
use
interferon
alpha
chemotherapi
use
antivir
treatment
consid
without
benefit
imatinib
show
promis
result
hivrel
ks
patient
syndrom
caus
primari
ebv
infect
includ
infecti
mononucleosi
chronic
activ
ebv
infect
xlink
lymphoprolif
syndrom
hct
patient
ebv
caus
lifethreaten
complic
post
transplant
lymphoprolif
disord
ptld
endorgan
diseas
encephalitismyel
pneumonia
hepat
detail
ebvptld
present
chap
donor
ebv
seroposit
contribut
also
risk
cgvhd
patient
acut
leukemia
allohct
patient
donor
test
ebv
ab
hct
sinc
ebv
seromismatch
risk
factor
ptld
select
ebvmatch
donor
possibl
might
benefici
ebvptld
hct
usual
donor
origin
ebv
might
transmit
graft
risk
ebvptld
higher
donor
seroposit
ebv
reactiv
subclin
requir
therapi
detail
treatment
ebvptld
present
chap
hsv
reactiv
caus
either
type
usual
associ
local
mucocutan
diseas
orofaci
region
less
frequent
esophag
genit
area
uncommon
manifest
pneumonia
hepat
mening
enceph
patient
test
hsv
antibodi
hsct
diagnosi
mucocutan
hsv
diseas
suspect
clinic
ground
diagnosi
usual
verifi
pcr
pcr
csf
techniqu
choic
diagnosi
hsv
mening
enceph
primari
hsv
infect
hsct
patient
unusu
antivir
drug
prophylaxi
thu
recommend
hsvseroneg
patient
hsct
might
need
vzv
see
hsvseroposit
patient
undergo
allohsct
receiv
antivir
drug
prophylaxi
iv
acyclovir
mgm
mgkg
oral
acyclovir
mgday
oral
valaciclovir
mgday
famciclovir
mg
day
use
durat
depend
also
prophylaxi
vzv
see
indic
given
least
week
hsct
vzvseroneg
patient
iv
acyclovir
mgm
mgkg
day
therapi
choic
sever
mucocutan
viscer
hsv
diseas
oral
acyclovir
mg
day
valaciclovir
mgday
famciclovir
mgday
day
consid
altern
less
seriou
manifest
hsv
diseas
hsv
pneumonia
hsv
mening
enceph
iv
acyclovir
mgm
mg
kg
least
day
recommend
hsv
resist
occur
approxim
patient
mediat
mutat
hsv
thymidin
kinas
foscarnet
cidofovir
secondlin
therapi
primari
infect
varicella
occur
rare
hsct
might
sever
clinic
cours
reactiv
herp
zoster
frequent
complic
prolong
neuralgia
common
unless
longterm
antivir
prophylaxi
given
clinic
sever
symptom
includ
dissemin
infect
similar
varicella
viscer
diseas
present
sever
abdomin
pain
acut
hepat
rare
enceph
retin
necrosi
pneumon
patient
test
vzv
antibodi
hsct
rash
clinic
varicella
zoster
usual
characterist
howev
case
dissemin
hsv
similar
appear
pcr
vesicular
materi
vzv
hsv
differenti
viscer
vzv
diseas
occur
without
rash
pcr
blood
diagnost
vzvseroposit
patient
given
antivir
prophylaxi
least
month
end
therapi
prophylaxi
given
acyclovir
mg
children
mgkg
valacyclovir
mg
seroneg
patient
expos
vzv
postexposur
prophylaxi
acyclovir
valacyclovir
recommend
prophylaxi
start
soon
possibl
continu
day
exposit
firstlin
therapi
varicella
dissemin
zoster
viscer
diseas
acyclovir
mg
iv
local
limit
infect
oral
valaciclovir
mg
acyclovir
mg
children
mgkg
famciclovir
mg
given
lesion
crust
usual
day
case
resist
acyclovir
secondlin
therapi
foscarnet
mgkg
cidofovir
mgkg
weekli
togeth
probenecid
hydrat
vzig
recommend
case
report
exist
cellular
therapi
vzv
infect
adv
transmit
mainli
person
person
howev
persist
epitheli
cell
lymphoid
tissu
reactiv
children
frequent
affect
adult
spectrum
advassoci
diseas
hsct
patient
rang
mild
gastroenter
respiratori
symptom
sever
hemorrhag
enter
hemorrhag
cystiti
nephriti
hepat
pneumonia
enceph
myocard
multipl
organ
involv
risk
factor
adv
infectiondiseas
includ
haploident
urd
graft
cbt
tcd
gvhd
iiiiv
sever
lymphopenia
treatment
alemtuzumab
advdna
qpcr
monitor
qpcr
adv
viremia
pb
recommend
least
weekli
basi
patient
least
one
risk
factor
qpcr
also
recommend
case
clinic
suspicion
adv
infect
diseas
nonpharmacolog
prophylaxi
mandatori
strict
isol
hygien
measur
patient
shed
viru
absolut
necessari
prevent
horizont
transmiss
nosocomi
outbreak
prophylact
antivir
therapi
avail
antivir
drug
recommend
patient
especi
children
increas
viral
load
least
one
risk
factor
receiv
preemptiv
antivir
treatment
cidofovir
mgkgweek
week
thereaft
everi
week
patient
probabl
proven
adv
diseas
treat
iv
cidofovir
mgkg
weekli
least
three
dose
thereaft
everi
week
togeth
hyperhydr
oral
probenecid
ribavirin
recommend
adv
donorderiv
advspecif
ctl
option
clinic
nonrespond
patient
oral
brincidofovir
mgkg
twice
weekli
might
obtain
compassion
use
influenza
yearli
occur
respiratori
viral
infect
outbreak
differ
size
depend
circul
strain
influenza
sever
infect
hsct
recipi
risk
lower
tract
diseas
ltd
report
high
mortal
vari
differ
report
risk
ltd
higher
occur
prior
condit
earli
hsct
virus
resist
neuraminidas
inhibitor
new
viral
strain
recent
swine
flu
symptom
similar
immunecompet
individu
respiratori
symptom
vari
mild
lifethreaten
symptom
gi
symptom
cn
symptom
also
occur
secondari
bacteri
infect
uncommon
sever
commerci
test
detect
either
nucleic
acid
influenza
antigen
avail
sinc
symptom
frequent
uncharacterist
multiplex
test
detect
differ
respiratori
virus
frequent
use
import
prophylact
measur
vaccin
recommend
yearli
hsct
recipi
efficaci
vaccin
vari
season
season
depend
fit
strain
use
prepar
vaccin
circul
strain
immun
respons
vaccin
better
given
least
month
hsct
although
vaccin
consid
month
hsct
outbreak
situat
second
dose
vaccin
consid
antivir
prophylaxi
gener
recommend
consid
patient
expos
infect
individu
standard
therapi
neuraminidas
inhibitor
mainli
oseltamivir
zanamivir
although
studi
shown
efficaci
specif
hsct
recipi
recogn
normal
recommend
durat
day
often
short
sinc
viral
excret
might
continu
long
time
resist
oseltamivir
rare
although
variabl
strain
circul
particular
season
respiratori
virus
carv
infect
carv
includ
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
metapneumoviru
rhinovirus
coronavirus
common
hsct
recipi
infect
mild
caus
upper
respiratori
symptom
ltd
occur
importantli
carv
infect
occur
start
condit
associ
sever
symptom
increas
nrm
therefor
defer
start
condit
shall
consid
least
symptomat
patient
multiplex
pcr
test
differ
carv
today
use
techniqu
avail
measur
avoid
nosocomi
spread
infect
therapi
carv
proven
efficaci
control
trial
ribavirin
either
given
inhal
system
suggest
reduc
risk
progress
upper
respiratori
tract
rsv
infect
ltd
possibl
reduc
mortal
rsv
pneumonia
licens
therapi
avail
carv
reactiv
ubiquit
neurotrop
john
cunningham
polyomaviru
jcv
may
caus
pml
rare
opportunist
sever
diseas
cn
pml
awar
increas
follow
introduct
new
immunomodulatori
treatment
natalizumab
rituximab
efalizumab
infliximab
brentuximab
fingolimod
dimethyl
fumar
azathioprin
tacrolimu
mmf
jcvdna
pcr
especi
csf
also
multiplex
pcr
new
option
highresolut
melt
analysi
pcrhrm
diagnosi
jcv
patient
pml
profound
suppress
cellular
immun
tlymphopenia
may
constitut
primari
pml
risk
factor
use
specif
treatment
current
avail
applic
gcsf
may
facilit
immun
reconstitut
jcv
clearanc
csf
bkvspecif
ctl
might
demonstr
antijcv
activ
due
viru
homolog
bkv
see
chap
hemorrhag
cystiti
renal
dysfunct
enter
transmiss
via
persontoperson
contact
predomin
way
spread
infect
hav
hsct
recipi
increas
risk
sosvod
hav
associ
aplast
anemia
due
scarciti
chronic
hav
infect
blood
product
hsct
donor
routin
test
hav
pcr
prefer
method
hsct
set
liver
function
test
lft
perform
donor
hsc
harvest
donor
abnorm
lft
test
antihavigm
hav
detect
donat
delay
havrna
longer
detect
donor
hsct
recommend
donor
recipi
virem
hav
increas
risk
sosvod
vaccin
consid
haviggneg
patient
risk
symptomat
primari
infect
even
case
hbsag
seroconvers
hbv
probabl
persist
lifelong
nucleu
hepatocyt
hbv
reactiv
treatmentinduc
loss
immun
control
hepat
includ
case
fulmin
hepat
failur
typic
occur
immun
system
reconstitut
de
novo
recognit
destruct
hbvinfect
hepatocyt
fibros
cholestat
hepat
consequ
hbv
reactiv
casefat
rate
hbv
reactiv
high
patient
hematolog
malign
donor
recipi
must
screen
antihbsag
antihbc
antihb
hbvdna
antihbc
detect
antivir
prophylaxi
given
antihbcposit
patient
receiv
graft
hbvinfect
donor
tenofovir
entecavir
drug
choic
vaccin
antihbcneg
antihbsneg
patient
hsct
recommend
doubl
vaccin
dose
may
requir
achiev
antihb
respons
immunocompromis
patient
month
vaccin
antihbcneg
antihbsneg
stem
cell
donor
hsct
harvest
consid
acceler
singledos
day
schedul
may
altern
convent
protocol
indic
treatment
includ
hbsagposit
patient
vaccin
addit
hepat
b
immun
globulin
consid
set
antivir
treatment
start
begin
ist
tenofovir
entecavir
drug
choic
treatment
continu
year
withdraw
ist
longer
recipi
cgvhd
patient
expos
deplet
ab
assess
liver
fibrosi
hcvrnaposit
recipi
recommend
close
monitor
essenti
patient
known
underli
fibrosi
liver
fibrosi
risk
factor
sosvod
drug
toxic
risk
acut
flareup
higher
patient
rituximabcontain
treatment
regimen
cirrhosi
wors
outcom
clearli
document
hsct
close
monitor
lft
hcvrna
recommend
infect
patient
hcvrnaposit
donor
could
consid
donor
option
consid
inferior
case
donor
rapidli
evalu
hepatologist
treatment
directli
act
antivir
consid
presenc
hcvrna
posit
recipi
constitut
contraind
hsct
antivir
therapi
consid
possibl
postpon
hsct
allow
complet
treatment
cours
antivir
treatment
consid
hcvrnaposit
hematolog
patient
hematolog
diseas
brought
control
done
consult
expert
hepatologist
hev
exist
least
four
differ
subtyp
spread
either
water
undercook
food
blood
transfus
main
sourc
spread
vari
differ
part
world
infect
water
common
rout
resourcepoor
area
area
common
rout
spread
via
undercook
food
produc
infect
anim
hev
infect
hsct
recipi
usual
mildli
symptomat
although
acut
hepat
jaundic
report
also
fatal
infect
pregnant
women
probabl
import
clinic
pictur
hsct
recipi
chronic
hepat
sinc
rapid
progress
cirrhosi
report
patient
serolog
detect
previous
infect
patient
pcr
detect
acut
chronic
infect
none
avail
ribavirin
suggest
treatment
chronic
infect
base
case
report
small
case
seri
howev
control
data
exist
norovirus
common
caus
foodborn
diseas
acut
nonbacteri
gastroenter
worldwid
preval
adult
among
pediatr
transplant
recipi
diarrhea
requir
hospit
icu
admiss
recurr
rate
risk
factor
second
hsct
intestin
gvhd
children
noroviru
caus
sever
prolong
diseas
complic
enter
fever
recurr
hospit
dehydr
chronic
diarrhea
acut
renal
failur
weight
loss
malnutrit
pneumatosi
intestinali
periton
secondari
bacteremia
death
viral
rna
rtpct
stool
nonpharmacolog
prophylaxi
mandatori
strict
isol
hygien
measur
patient
shed
viru
absolut
necessari
prevent
horizont
transmiss
nosocomi
outbreak
symptomat
report
indic
oral
human
immunoglobulin
therapi
specif
therapi
avail
zikv
infect
transmit
mainli
aed
aegypti
mosquito
sexual
contact
blood
transfus
typic
mild
asymptomat
diseas
gener
popul
diseas
selflimit
febril
ill
last
day
infect
follow
neurolog
consequ
includ
guillainbarr
syndrom
microcephali
congenit
neurolog
syndrom
vertic
transmiss
infect
mother
fetu
pregnanc
direct
detect
zikvrna
specif
viral
antigen
blood
tissu
cell
import
area
zikv
transmiss
test
neg
presenc
zikv
donor
diagnos
zikv
infect
return
affect
area
defer
least
day
cessat
symptom
deferr
least
month
sexual
contact
person
risk
open
access
chapter
licens
term
creativ
common
attribut
intern
licens
http
permit
use
share
adapt
distribut
reproduct
medium
format
long
give
appropri
credit
origin
author
sourc
provid
link
creativ
common
licens
indic
chang
made
imag
third
parti
materi
chapter
includ
chapter
creativ
common
licens
unless
indic
otherwis
credit
line
materi
materi
includ
chapter
creativ
common
licens
intend
use
permit
statutori
regul
exce
permit
use
need
obtain
permiss
directli
copyright
holder
epidemiolog
latent
especi
cmv
endem
especi
carv
hepatotrop
virus
main
problem
patient
hsct
diagnosi
viral
diagnost
hsct
requir
qpcr
multiplex
pcr
prophylaxi
treatment
prophylaxi
pharmacolog
environment
preemptiv
treatment
necessari
patient
hsct
undergo
vaccin
accord
current
recommend
outcom
viral
infect
contribut
nonrelaps
mortal
hsct
